Liquid chromatography-electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasma

Archives of Pharmacal Research

Volumn 30, Issue 7, 2007, Pages 905-910

  Young, Hoon Kim ^a   Hye, Young Ji ^a   Park, Eun Seok ^b   Chae, Soo Wan ^c   Hye, Suk Lee ^a  

^a Wonkwang University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

Human plasma; LC ESI MS MS; Lornoxicam; Pharmacokinetics

Indexed keywords

EID: 34547617217     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02978844     Document Type: Article

References (7)

1. Bonnabry, P., Leemann, T., and Dayer, P., Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur. J. Clin. Pharmacol., 49, 305-308 (1996).
2. Matuszewski, B. K., Constanzer, M. L., and Chavez-Eng, C. M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem., 75, 3019-3030 (2003).
3. Radhofer-Welte, S. and Dittrich, P., Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J. Chromatogr. B, 707, 151-159 (1998).
4. Radhofer-Welte, S. and Rabasseda, X., Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today, 36, 55-76 (2000).
5. Skjodt, N.M. and Davies, N.M., Clinical pharmacokinetics of lornoxicam, a short half-life oxicam. Clin. Pharmacokinet., 34, 421-428 (1998).
6. Suwa, T., Urano, H., Shinohara, Y., and Kokatsu, J., Simultaneous high-performance liquid chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J. Chromatogr., 617, 105-110 (1993).
7. Zeng, Y., Chen, X., Zhang, Y., and Zhong D., Determination of lornoxicam in human plasma by LC/MS/MS. Acta Pharm. Sin., 39, 132-135 (2004).